The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients.

ABSTRACT: Despite major improvements in combatting metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of reports supporting an "obesity paradox," in which patients who are overweight or mildly obese may exhibit a survival benefit in patients who received immune checkpoint inhibitors. We studied the relationship between body mass index and progression-free survival and overall survival in a cohort of 423 metastatic melanoma patients receiving immunotherapy, enrolled and prospectively followed up in the NYU Interdisciplinary Melanoma Cooperative Group database. We analyzed this association stratified by first vs. second or greater-line of treatment and treatment type adjusting for age, gender,

SUBMITTER: Donnelly D 

PROVIDER: S-EPMC6700794 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature